Neurolymphomatosis: Diagnosis, management, and outcomes in patients treated with rituximab

Neuro-Oncology

Volumn 12, Issue 2, 2010, Pages 212-215

  Gan, Hui K ^a   Azad, Arun ^a   Cher, Lawrence ^a   Mitchell, Paul L R ^a  

^a AUSTIN HOSPITAL   (Australia)

Author keywords

Chemotherapy; Incidence; Neurolymphomatosis; PET; Rituximab

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; IFOSFAMIDE; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; CANCER COMBINATION CHEMOTHERAPY; CANCER PALLIATIVE THERAPY; CANCER REGRESSION; CASE REPORT; CRANIAL NERVE TUMOR; DRUG MEGADOSE; DRUG WITHDRAWAL; FATALITY; FEMALE; HUMAN; LARGE CELL LYMPHOMA; LYMPHOMATOSIS; MALE; PERIPHERAL NERVE TUMOR; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PERIPHERAL NERVOUS SYSTEM NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; TREATMENT OUTCOME;

EID: 75849130360     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nop021     Document Type: Article

References (19)

1. Baehring JM, Damek D, Martin EC, Betensky RA, Hochberg FH. Neurolymphomatosis. Neuro-oncology. 2003;5:104-115.
2. Baehring J, Cooper D. Neurolymphomatosis. J Neurooncol. 2004;68:243-244.
3. Rosso SM, de Bruin HG, Wu KL, van den Bent MJ. Diagnosis of neurolymphomatosis with FDG PET. Neurology. 2006;67:722-723.
4. Ozturk E, Arpaci F, Kocaoglu M, Arslan N, Bulakbasi N, Ozguven M. Detection of widespread neurolymphomatosis with 18F-FDG PET. Eur J Nucl Med Mol Imaging. 2006;33:975-976.
5. Kim JH, Jang JH, Koh S-B. A case of neurolymphomatosis involving cranial nerves: MRI and fusion PET-CT findings. J Neurooncol. 2006;80:209-210.
6. Strobel K, Pestalozzi B, Ciernik I, Schaefer NG, Koma AY, Hany TF. Changing PET/CT manifestation of neurolymphomatosis. Eur J Nucl Med Mol Imaging. 2006;33:1244.
7. Yazawa S, Ohi T, Shiomi K, Takashima N, Kyoraku I, Nakazato M. Brachial plexus neurolymphomatosis: a discrepancy between electrophysiological and radiological findings. Intern Med. 2007;46:533-534.
8. Rahmani M, Birouk N, Amarti A, et al. T-cell lymphoma revealed by a mononeuritis multiplex: case report and review of literature. Rev Neurol (Paris). 2007;163:462-470.
9. Grisold W, Klimpfinger M, Maehr B, et al. Peripheral nerve involvement in lymphoma: the meninges as the crucial barrier between meningoradicular spread and neurolymphomatosis. J Peripher Nerv Syst. 2007;12:58-60.
10. Kanter P, Zeidman A, Streifler J, et al. PET-CT imaging of combined brachial and lumbosacral neurolymphomatosis. Eur J Haematol. 2005;74:66-69.
11. Hughes RA, Britton T, Richards M. Effects of lymphoma on the peripheral nervous system. J R Soc Med. 1994;87:526-530.
12. Bokstein F, Goor O, Shihman B, et al. Assessment of neurolymphomatosis by brachial plexus biopsy and PET/CT. Report of a case. J Neurooncol. 2005;72:163-167.
13. Ferner RE, Golding JF, Smith M, et al. [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study. Ann Oncol. 2008;19:390-394.
14. Cardona S, Schwarzbach M, Hinz U, et al. Evaluation of F18-deoxyglucose positron emission tomography (FDG-PET) to assess the nature of neurogenic tumours. Eur J Surg Oncol. 2003;29:536-541.
15. Bredella MA, Torriani M, Hornicek F, et al. Value of PET in the assessment of patients with neurofibromatosis type 1. AJR Am J Roentgenol. 2007;189:928-935.
16. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005;23:4117-4126.
17. Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol. 2006;24:3121-3127.
18. Wong ET. Management of central nervous system lymphomas using monoclonal antibodies: challenges and opportunities. Clin Cancer Res. 2005;11:7151s-7157s.
19. Olsson Y. Microenvironment of the peripheral nervous system under normal and pathological conditions. Crit Rev Neurobiol. 1990;5:265-311.